- Home
- ACET vs FNGR Comparison
ACET vs FNGR Comparison
Compare ACET & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACET | FNGR |
|---|---|---|
| Founded | 1947 | 2016 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 74.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACET | FNGR |
|---|---|---|
| Price | $6.98 | $1.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $65.33 | N/A |
| AVG Volume (30 Days) | 201.4K | ★ 203.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.41 | $1.05 |
| 52 Week High | $17.44 | $5.20 |
Technical Indicators
Market Signals| Indicator | ACET | FNGR |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 40.44 |
| Support Level | $6.42 | $1.06 |
| Resistance Level | $7.30 | $1.18 |
| Average True Range (ATR) | 0.62 | 0.10 |
| MACD | -0.30 | -0.01 |
| Stochastic Oscillator | 28.38 | 6.41 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.